The past decade has seen groundbreaking research in the field of aging, which revealed a fascinating phenomenon:
Transfusion of blood from young mice to old mice showed a significant slowing of the rate of aging.
This discovery aroused great interest and led to the search for the modern "fountain of youth", in the form of treatments based on young blood transfusions.
In 2017, the start-up company Ambrosia caused a stir in the medical world
when it began offering experimental treatments of young plasma transfusions (the liquid part of the blood) at a price of $8,000 per liter.
The treatment was based on the assumption that components of young blood can stimulate biological processes in the body and slow down aging.
However, the "Fountain of Youth" approach also raised many concerns.
The lack of established clinical trials in humans has raised questions about the safety and effectiveness of the treatment.
In addition, ethical questions have been raised regarding an approach that could turn aging into a "privilege" for those with means.
In February 2024, a heavy blow came to the Ambrosia company and the young blood transfusion idea.
The American Food and Drug Administration (FDA) issued a harsh statement in which it stated that there is no clinical evidence for the treatment of young plasma transfusions against age-related diseases. As a result, the company was closed and the treatment was shelved.
References:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764071/
